Predictors for starting depot administration of risperidone in chronic users of antipsychotics.

  title={Predictors for starting depot administration of risperidone in chronic users of antipsychotics.},
  author={Jelle Vehof and Maarten J Postma and Richard Bruggeman and Lolkje de Jong-van den Berg and Paul B van den Berg and Ronald P. Stolk and Huibert Burger},
  journal={Journal of clinical psychopharmacology},
  volume={28 6},
BACKGROUND Risperidone long-acting injectable (RLAI), the first second-generation depot antipsychotic, has extensively been studied before introduction. Thereafter, questions about the type of patients actually treated with RLAI in daily practice remain to be answered for making valid antipsychotic treatment comparisons involving RLAI in observational studies. OBJECTIVE We aimed to determine in chronic antipsychotic users who switched treatment, predictors for the prescription of (1) depot… CONTINUE READING


Publications citing this paper.
Showing 1-7 of 7 extracted citations


Publications referenced by this paper.
Showing 1-10 of 30 references

A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of Journal of Clinical Psychopharmacology

  • J Mc Grath, S Saha, J Welham
  • Volume 28, Number
  • 2008

Cost effectiveness of long - acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA

  • BM Heeg, G Aalst, U Arend
  • Pharmacoeconomics
  • 2005

Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association

  • AF Lehman, JA Lieberman, LB Dixon
  • Am J Psychiatry
  • 2004
2 Excerpts

Similar Papers

Loading similar papers…